Detalhe da pesquisa
1.
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial.
Br J Haematol;
193(3): 561-569, 2021 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33555030
2.
Novel immunotherapies in multiple myeloma - chances and challenges.
Haematologica;
106(10): 2555-2565, 2021 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34196164
3.
Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care.
BMC Cancer;
20(1): 245, 2020 Mar 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32293347
4.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med;
375(8): 754-66, 2016 Aug 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27557302
5.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
BMC Cancer;
19(1): 504, 2019 May 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31138244
6.
Induced arginine transport via cationic amino acid transporter-1 is necessary for human T-cell proliferation.
Eur J Immunol;
46(1): 92-103, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26449889
7.
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Haematologica;
100(7): 964-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25840597
8.
Teaming up for CAR-T cell therapy.
Haematologica;
104(12): 2335-2336, 2019 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31787616
9.
Does Systemic Hematological Therapy Influence the Course of Paraproteinemic Keratopathy?
J Clin Med;
13(2)2024 Jan 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38256698
10.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Leukemia;
38(3): 640-647, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38062124
11.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
J Clin Oncol;
42(1): 26-37, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37753960
12.
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.
Hematology;
29(1): 2320006, 2024 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38407192
13.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
J Clin Oncol;
: JCO2401008, 2024 Jun 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38879802
14.
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Lancet Haematol;
11(2): e101-e113, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38302221
15.
Arginine deficiency leads to impaired cofilin dephosphorylation in activated human T lymphocytes.
Int Immunol;
24(5): 303-13, 2012 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22345165
16.
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
Blood Cancer J;
13(1): 1, 2023 01 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36599831
17.
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.
J Clin Oncol;
41(8): 1600-1609, 2023 03 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36413710
18.
A drug repurposing approach for individualized cancer therapy based on transcriptome sequencing and virtual drug screening.
Comput Biol Med;
157: 106781, 2023 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36931205
19.
Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms?
Trends Immunol;
30(11): 522-30, 2009 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19775938
20.
SAMHD1 in cancer: curse or cure?
J Mol Med (Berl);
100(3): 351-372, 2022 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34480199